|
ES2963268T3
(es)
|
2015-07-31 |
2024-03-26 |
Immunewalk Therapeutics Inc |
Proteína 2 que contiene el dominio de esperma móvil e inflamación
|
|
GB201519481D0
(en)
*
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
BR112018071612A2
(pt)
|
2016-04-22 |
2019-02-19 |
Alligator Bioscience Ab |
polipeptídeos biespecíficos inovadores contra cd137
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
JP7085709B2
(ja)
|
2016-06-20 |
2022-06-17 |
エフ－スター セラピューティクス リミテッド |
Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
|
|
US10052215B2
(en)
|
2016-06-29 |
2018-08-21 |
Globus Medical, Inc. |
Expandable fusion device and method of installation thereof
|
|
US12544236B2
(en)
|
2016-06-29 |
2026-02-10 |
Globus Medical Inc. |
Expandable fusion device and method of installation thereof
|
|
GB201611530D0
(en)
*
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
BR112019000512A2
(pt)
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
EP3515951B1
(en)
|
2016-09-23 |
2024-02-28 |
Merus N.V. |
Binding molecules that modulate a biological activity expressed by a cell
|
|
GB201619652D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
UY37523A
(es)
*
|
2016-12-15 |
2018-07-31 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-ox40 y sus usos
|
|
BR112019017628A2
(pt)
*
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc. |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
MX2019012953A
(es)
*
|
2017-05-02 |
2020-02-12 |
Alligator Bioscience Ab |
Anticuerpo biespecifico contra ox40 y ctla-4.
|
|
IL270743B2
(en)
*
|
2017-05-19 |
2024-09-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
|
|
MX2019015885A
(es)
*
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
US11725060B2
(en)
*
|
2017-07-20 |
2023-08-15 |
Aptevo Reserch and Development LLC |
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
|
|
KR20250020679A
(ko)
|
2017-08-04 |
2025-02-11 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
CN111511762B
(zh)
*
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CA3086098A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CN112041336A
(zh)
*
|
2018-03-13 |
2020-12-04 |
脉管生物生长有限公司 |
针对mospd2和t细胞或nk细胞特异性分子的双特异性抗体
|
|
CN110467674B
(zh)
|
2018-05-11 |
2022-05-31 |
同润澳门一人有限公司 |
抗ox40的全人抗体及其制备方法和用途
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
AU2019301206B2
(en)
*
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
JP2022510218A
(ja)
*
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
WO2020127374A2
(en)
*
|
2018-12-17 |
2020-06-25 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
WO2020216947A1
(en)
|
2019-04-24 |
2020-10-29 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
MX2022001882A
(es)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
|
|
JP7634001B2
(ja)
*
|
2019-10-11 |
2025-02-20 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
４－１ｂｂに結合する抗体およびその用途
|
|
JP7702954B2
(ja)
*
|
2019-12-27 |
2025-07-04 |
ハイファイバイオ， インコーポレイテッド |
抗ｏｘ４０抗体およびその使用
|
|
US20230151102A1
(en)
|
2020-01-13 |
2023-05-18 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
CN115279406A
(zh)
|
2020-01-13 |
2022-11-01 |
阿帕特夫研究和发展有限公司 |
蛋白质治疗剂的调配物
|
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
IL301202A
(en)
|
2020-09-10 |
2023-05-01 |
Vascular Biogenics Ltd |
Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
|
|
WO2022094299A2
(en)
*
|
2020-10-30 |
2022-05-05 |
Janux Therapeutics, Inc. |
Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
|
|
KR20230167025A
(ko)
*
|
2021-02-17 |
2023-12-07 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도
|
|
US20240262920A1
(en)
|
2021-05-21 |
2024-08-08 |
Aptevo Research And Development Llc |
Dosing regimens for protein therapeutics
|
|
IL314993A
(en)
|
2022-02-23 |
2024-10-01 |
Xencor Inc |
Anti-cd28 x anti-psma antibodies
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
US20250043001A1
(en)
*
|
2023-03-14 |
2025-02-06 |
Xencor, Inc. |
Anti-cd28 compositions
|
|
CN121231764A
(zh)
*
|
2024-06-28 |
2025-12-30 |
江苏三联生物工程股份有限公司 |
蛋白芯片、基于多肽编码微阵列芯片的检测试剂盒及其应用
|